An overview of the main regulatory issues affecting the pharmaceutical industry

Discover what makes Pfizer CentreOne an Altogether Different Kind of CDMO.

The production of oral solid dosage (OSD) forms is becoming increasingly complex as innovative techniques and technologies make it easier to harness challenging active pharmaceutical ingredients (APIs) in new medicines. Here we examine the key offerings a reliable CMDO partner must provide to successfully help support your OSD on its journey to market, and explore how Pfizer CentreOne can help.

Throughout CPHI North America (Philadelphia, PA; April 25–27, 2023), we caught up with some of the exhibiting organisations to ask what the show brings to the North American pharmaceutical sector, and what is driving industry innovation in this region of the world.  

Welcome to Pfizer CentreOne. We’re a global CDMO embedded within Pfizer and a leading supplier of specialty APIs. Working with our customers, we combine our technical and commercial knowledge with open dialogue to solve challenges – we call this intelligent collaboration.

Follow along for live updates from the Content team as we bring you the latest from CPHI North America 2023 - from session talks, panel discussions, interviews, and more, there's a lot to discover with CPHI Online at the Pennsylvania Convention Center! 

Welcome to Pfizer CentreOne. We have a global network ready to deliver end-to-end analytical and manufacturing expertise. Collaborating with you, we can help take your molecule all the way from early clinical phases through commercial manufacture and lifecycle management.

Pfizer has the experience of taking molecules from lab to patient. Over the years we’ve learned invaluable lessons in the development of biologics and share our project management experience to support our customers’ drug strategies. Backed by Pfizer resources, we deliver technical expertise, global regulatory support and long-term supply.

Where QBD was the orchestral sheet music that determined how drug product development has been harmonized over the last 15 or so years, contemporary patient-centric risk-based approaches to drug development are the pop evolution. The music is still beautiful when produced well - but the focus is no longer on the full orchestra, it's on key players and moments. First - think McCartney and Lennon - one without the other and we don’t have the Beatles. The same can be said for collaboration between drug process development and commercial production colleagues. They are central to ensuring that products are easier to transfer and can be scaled, and that manufacturing challenges are identified early on and addressed proactively. In his keynote, Bernd Schümmelfeder Director-Team Leader PPD Business Development, Pfizer explores how lyrics (communication), rhythm (standardization), bass (structured development processes), and lead guitar (the use of smart technologies) throughout the drug development process come together to create beautiful music - a drug that gets to patients safely and at pace. Key areas for discussion include: Clear decision and inflection points to manage costs and prioritize projects with a higher probability of success Smart technologies like modeling to identify challenges early on and avoid late-stage pitfalls Use of platform technologies to simplify the tech transfer process and improve process robustness Areas to optimize the product development and manufacturing process to make it more efficient, cost-effective, and patient-focused